Corbus Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Corbus Pharmaceuticals's estimated annual revenue is currently $4.8M per year.
- Corbus Pharmaceuticals received $27.2M in venture funding in March 2017.
- Corbus Pharmaceuticals's estimated revenue per employee is $31,299
- Corbus Pharmaceuticals's total funding is $64M.
- Corbus Pharmaceuticals has 154 Employees.
- Corbus Pharmaceuticals grew their employee count by 19% last year.
- Corbus Pharmaceuticals currently has 21 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Phase Zero Desi...||$14M||52||6%||N/A||N/A|
What Is Corbus Pharmaceuticals?
Corbus Pharmaceuticals (NASDAQ: CRBP) is a Phase 3, clinical-stage pharmaceutical company focused on advancing the development and commercialization of novel therapies to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Corbus Pharma was named one of the Best Places To Work by Boston Business Journal in 2017. Our people are high-achievers, innovative, creative and, above all else, passionate about what we do in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus eythematosus.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Yuval Cohen||Chief Executive Officer, Director||Email Available|
|Mark Tepper||President/Chief Scientific Officer||Email Available|
|Sean Moran||Chief Financial Officer||Email Available|
|Charity Conner||Director Data Management|
|Jungeun Lee||Accounting Manager|
|Barbara White||Chief Medical Officer||Email Available|
|Robert Discordia||Chief Operating Officer||Email Available|
|Caitlin Cornwall||Clinical Trial Manager, Rare Disease|
|Timothy Thullen||Director, Toxicology|
|Erika Molignano||Director Of Quality Assurance|
Corbus Pharmaceuticals News
Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares are showing positive signals short-term as the stock has finished higher by 3.22% for ...
So we'll take a look at whether insiders have been buying or selling shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP).
While Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shareholders are probably generally happy, the stock hasn't had particularly ...
Corbus Pharmaceuticals Funding
|2014-06-04||$10.3M||Undisclosed||Aegis Capital Corp||Article|